Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 1487-1493, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tobler, L. H.
Right arrow Articles by Busch, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tobler, L. H.
Right arrow Articles by Busch, M. P.
Related Collections
Right arrow Arnold O. Beckman Conference
Right arrow Hematology
(Clinical Chemistry. 1997;43:1487-1493.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

History of posttransfusion hepatitis

Leslie H. Tobler1,a and Michael P. Busch1,2

1 Irwin Memorial Blood Centers, 270 Masonic Ave., San Francisco, CA 94118.

2 Department of Laboratory Medicine, University of California, San Francisco, CA 94143.
a Author for correspondence. Fax 415-775-3859; e-mail ltobler{at}ccnet.com

The risk of hepatitis virus transmission from transfusions has declined dramatically from that of the 1940s when posttransfusion hepatitis (PTH) was first appreciated. Introduction of hepatitis B surface antigen screening and conversion to volunteer donors for whole-blood donations in the late 1960s and early 1970s led to substantial reduction in PTH cases. However, up to 10% of the recipients continued to develop PTH, most cases of which were attributed to an unknown non-A, non-B viral agent. Implementation of surrogate marker testing (i.e., alanine aminotransferase and anti-hepatitis B virus core antigen) for residual non-A, non-B hepatitis in the late 1980s reduced the per unit risk of PTH from 1 in 200 to about 1 in 400. Hepatitis C virus was discovered in 1989 and quickly was established as the causative agent of >90% of non-A, non-B PTH. Introduction of progressively improved antibody assays in the early 1990s reduced the risk of PTH due to hepatitis C virus to about 1 in 100 000. Although additional hepatitis viruses exist (e.g., hepatitis G virus), these appear to be minor contributors to clinical PTH, which has been virtually eradicated.




The following articles in journals at HighWire Press have cited this article:


Home page
 NEJMHome page
S. L. Stramer, S. A. Glynn, S. H. Kleinman, D. M. Strong, S. C. M.T. (A.S.C.P.), D. J. Wright, R. Y. Dodd, M. P. Busch, and the National Heart, Lung, and Blood Institute Nucl
Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid-Amplification Testing
N. Engl. J. Med., August 19, 2004; 351(8): 760 - 768.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
J. A. Salomon, M. C. Weinstein, J. K. Hammitt, and S. J. Goldie
Empirically Calibrated Model of Hepatitis C Virus Infection in the United States
Am. J. Epidemiol., October 15, 2002; 156(8): 761 - 773.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
L. R. Fischer, D. H. Tope, K. S. Conboy, B. D. Hedblom, E. Ronberg, D. K. Shewmake, and J. C. Butler
Screening for Hepatitis C Virus in a Health Maintenance Organization
Arch Intern Med, June 12, 2000; 160(11): 1665 - 1673.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Vogt, T. Lang, G. Frosner, C. Klingler, A. F. Sendl, A. Zeller, B. Wiebecke, B. Langer, H. Meisner, and J. Hess
Prevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor Screening
N. Engl. J. Med., September 16, 1999; 341(12): 866 - 870.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.